Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 5.97
SPPI's Cash-to-Debt is ranked lower than
63% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. SPPI: 5.97 )
Ranked among companies with meaningful Cash-to-Debt only.
SPPI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2  Med: 6.28 Max: 17918
Current: 5.97
0.2
17918
Equity-to-Asset 0.73
SPPI's Equity-to-Asset is ranked higher than
56% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SPPI: 0.73 )
Ranked among companies with meaningful Equity-to-Asset only.
SPPI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.58 Max: 0.95
Current: 0.73
0.2
0.95
Debt-to-Equity 0.12
SPPI's Debt-to-Equity is ranked higher than
71% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. SPPI: 0.12 )
Ranked among companies with meaningful Debt-to-Equity only.
SPPI' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.68  Med: 0.2 Max: 0.69
Current: 0.12
-0.68
0.69
Debt-to-EBITDA -0.54
SPPI's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. SPPI: -0.54 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SPPI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.27  Med: -0.56 Max: 0.81
Current: -0.54
-23.27
0.81
Piotroski F-Score: 3
Altman Z-Score: 9.00
Beneish M-Score: -3.02
WACC vs ROIC
16.08%
-53.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -77.52
SPPI's Operating Margin % is ranked higher than
53% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. SPPI: -77.52 )
Ranked among companies with meaningful Operating Margin % only.
SPPI' s Operating Margin % Range Over the Past 10 Years
Min: -77.52  Med: -34.57 Max: 30.17
Current: -77.52
-77.52
30.17
Net Margin % -64.81
SPPI's Net Margin % is ranked higher than
52% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. SPPI: -64.81 )
Ranked among companies with meaningful Net Margin % only.
SPPI' s Net Margin % Range Over the Past 10 Years
Min: -71.08  Med: -43.76 Max: 35.19
Current: -64.81
-71.08
35.19
ROE % -30.11
SPPI's ROE % is ranked higher than
53% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. SPPI: -30.11 )
Ranked among companies with meaningful ROE % only.
SPPI' s ROE % Range Over the Past 10 Years
Min: -51.49  Med: -24.2 Max: 39.19
Current: -30.11
-51.49
39.19
ROA % -18.84
SPPI's ROA % is ranked higher than
59% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. SPPI: -18.84 )
Ranked among companies with meaningful ROA % only.
SPPI' s ROA % Range Over the Past 10 Years
Min: -27.95  Med: -12.49 Max: 23.98
Current: -18.84
-27.95
23.98
ROC (Joel Greenblatt) % -17918.42
SPPI's ROC (Joel Greenblatt) % is ranked lower than
87% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. SPPI: -17918.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SPPI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -18624.28  Med: -1954.97 Max: 3089.46
Current: -17918.42
-18624.28
3089.46
3-Year Revenue Growth Rate -19.50
SPPI's 3-Year Revenue Growth Rate is ranked lower than
72% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. SPPI: -19.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SPPI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.8 Max: 202.1
Current: -19.5
0
202.1
3-Year EBITDA Growth Rate -103.30
SPPI's 3-Year EBITDA Growth Rate is ranked lower than
96% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. SPPI: -103.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SPPI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.6 Max: 71.1
Current: -103.3
0
71.1
3-Year EPS without NRI Growth Rate -14.70
SPPI's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. SPPI: -14.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SPPI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2 Max: 70.1
Current: -14.7
0
70.1
GuruFocus has detected 5 Warning Signs with Spectrum Pharmaceuticals Inc SPPI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SPPI's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

SPPI Guru Trades in Q2 2017

Jim Simons 6,071,817 sh (+6.90%)
Barrow, Hanley, Mewhinney & Strauss 231,745 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2017

SPPI Guru Trades in Q3 2017

Jeremy Grantham 15,300 sh (New)
PRIMECAP Management 4,006,000 sh (New)
Ken Fisher 179,209 sh (New)
Jim Simons 6,659,317 sh (+9.68%)
Barrow, Hanley, Mewhinney & Strauss 231,745 sh (unchged)
» More
Q4 2017

SPPI Guru Trades in Q4 2017

Leucadia National 18,934 sh (New)
Jeremy Grantham 21,600 sh (+41.18%)
PRIMECAP Management 4,566,000 sh (+13.98%)
Ken Fisher 200,252 sh (+11.74%)
Steven Cohen 800,000 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Jim Simons 6,180,917 sh (-7.18%)
» More
Q1 2018

SPPI Guru Trades in Q1 2018

PRIMECAP Management 7,420,000 sh (+62.51%)
Steven Cohen 550,000 sh (unchged)
Leucadia National Sold Out
Jeremy Grantham Sold Out
Ken Fisher 198,695 sh (-0.78%)
Jim Simons 5,580,000 sh (-9.72%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Reduce -0.78%$16.09 - $23.07 $ 18.76-5%198,695
Leucadia National 2018-03-31 Sold Out 0.03%$16.09 - $23.07 $ 18.76-5%0
Ken Fisher 2017-12-31 Add 11.74%$13.36 - $20.73 $ 18.764%200,252
Leucadia National 2017-12-31 New Buy0.03%$13.36 - $20.73 $ 18.764%18,934
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Sold Out $13.36 - $20.73 $ 18.764%0
Ken Fisher 2017-09-30 New Buy$7.28 - $13.49 $ 18.76110%179,209
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:MDGL, NAS:XLRN, NAS:ATRA, NAS:RGEN, NAS:DNLI, XKRX:005250, OSTO:VITR, NAS:MYOK, HKSE:06826, NAS:ENTA, NAS:AIMT, NYSE:CBM, NAS:EDIT, BOM:539268, NAS:INSM, NAS:ESPR, XSWX:SFZN, SZSE:002030, NAS:SGMO, NAS:IMGN » details
Traded in other countries:NTR.Germany,
Headquarter Location:USA
Spectrum Pharmaceuticals Inc is a biotechnology company in the United States. It develops drugs to cure serious diseases such as chemotherapy-induced neutropenia in patients with breast cancer.

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. As an oncology products manufacturer, it develops drugs to combat various kinds of tumors. The SPI-2012 is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN addresses immediate intravesical instillation and post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Its other products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA.

Ratios

vs
industry
vs
history
PB Ratio 6.00
SPPI's PB Ratio is ranked lower than
55% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SPPI: 6.00 )
Ranked among companies with meaningful PB Ratio only.
SPPI' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.15 Max: 6.91
Current: 6
0.64
6.91
PS Ratio 12.86
SPPI's PS Ratio is ranked lower than
51% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPPI: 12.86 )
Ranked among companies with meaningful PS Ratio only.
SPPI' s PS Ratio Range Over the Past 10 Years
Min: 1.07  Med: 3.2 Max: 19.95
Current: 12.86
1.07
19.95
EV-to-EBIT -17.50
SPPI's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. SPPI: -17.50 )
Ranked among companies with meaningful EV-to-EBIT only.
SPPI' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.8  Med: -4.2 Max: 63.5
Current: -17.5
-25.8
63.5
EV-to-EBITDA -24.20
SPPI's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. SPPI: -24.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
SPPI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1739.5  Med: -2.6 Max: 128
Current: -24.2
-1739.5
128
EV-to-Revenue 13.55
SPPI's EV-to-Revenue is ranked higher than
50% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. SPPI: 13.55 )
Ranked among companies with meaningful EV-to-Revenue only.
SPPI' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.1  Med: 2.7 Max: 16.5
Current: 13.55
-1.1
16.5
Current Ratio 2.97
SPPI's Current Ratio is ranked lower than
68% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. SPPI: 2.97 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.97 Max: 16.82
Current: 2.97
0.56
16.82
Quick Ratio 2.91
SPPI's Quick Ratio is ranked lower than
64% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. SPPI: 2.91 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.89 Max: 16.8
Current: 2.91
0.56
16.8
Days Inventory 68.32
SPPI's Days Inventory is ranked higher than
71% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. SPPI: 68.32 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s Days Inventory Range Over the Past 10 Years
Min: 55.77  Med: 93.47 Max: 281.63
Current: 68.32
55.77
281.63
Days Sales Outstanding 93.88
SPPI's Days Sales Outstanding is ranked lower than
70% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. SPPI: 93.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.22  Med: 101.41 Max: 138.24
Current: 93.88
68.22
138.24
Days Payable 246.29
SPPI's Days Payable is ranked lower than
99.99% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. SPPI: 246.29 )
Ranked among companies with meaningful Days Payable only.
SPPI' s Days Payable Range Over the Past 10 Years
Min: 89.64  Med: 202.3 Max: 331.71
Current: 246.29
89.64
331.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.20
SPPI's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. SPPI: -15.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPPI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -149.9  Med: -23 Max: -3.6
Current: -15.2
-149.9
-3.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.37
SPPI's Price-to-Net-Cash is ranked lower than
78% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. SPPI: 17.37 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SPPI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.86  Med: 7.93 Max: 77.54
Current: 17.37
0.86
77.54
Price-to-Net-Current-Asset-Value 12.42
SPPI's Price-to-Net-Current-Asset-Value is ranked lower than
71% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. SPPI: 12.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SPPI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.84  Med: 9.59 Max: 279.33
Current: 12.42
0.84
279.33
Price-to-Tangible-Book 11.10
SPPI's Price-to-Tangible-Book is ranked lower than
69% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. SPPI: 11.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SPPI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.66  Med: 6.86 Max: 581.43
Current: 11.1
0.66
581.43
Price-to-Intrinsic-Value-Projected-FCF 11.73
SPPI's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
68% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. SPPI: 11.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SPPI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.09  Med: 1.73 Max: 12.69
Current: 11.73
1.09
12.69
Price-to-Median-PS-Value 4.01
SPPI's Price-to-Median-PS-Value is ranked lower than
91% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. SPPI: 4.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SPPI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 2.55 Max: 3541.67
Current: 4.01
0.18
3541.67
Earnings Yield (Greenblatt) % -5.73
SPPI's Earnings Yield (Greenblatt) % is ranked higher than
53% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. SPPI: -5.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SPPI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1825.9  Med: -8.6 Max: 1754.4
Current: -5.73
-1825.9
1754.4

More Statistics

Revenue (TTM) (Mil) $129.76
EPS (TTM) $ -0.93
Beta2.44
Volatility81.06%
52-Week Range $5.47 - 23.50
Shares Outstanding (Mil)104.06

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 109 124 210
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.67 -0.37 0.12
EPS without NRI ($) -0.67 -0.37 0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}